Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 324647
1) use the Assays in any form for Internal Drug Development. No royalties or fees shall be payable by Licensee to Licensor in respect of this exercise of the rights so licensed;
2) Subject to royalty payments, commercially exploit the Assays in any form without restriction, including by the utilization of the Assays, in combination with screening and/or other technology owned by or licensed to Licensee, for the provision of services to Clients; by way of license of the Assays; and by way of sale of the Assays.
ADME Hardware Licensees ADME hardware known as CESCA described as Example of High throughput screening of gastrointestinal bioavailibility.
Jointly Developed Technology shall have the meaning in respect of technology which is created, invented or discovered in the course of carrying out any Project.
Licensor is focused on accelerating drug discovery from disease targets to clinical candidates through its iDiscovery-TM- technologies. Such technologies include (i) the IDEA-TM- ('In Vitro Determination for the Estimation of ADME (absorption, distribution, metabolism and excretion)') computerized predictive models for, among other things, the prediction and selection of compounds with essential drug-like characteristics for further development.
The collaboration combines Licensee's expertise in ultra high-throughput screening technology, miniaturized assay development and its detection expertise based on its proprietary single molecule detection technology with Licensor's capabilities in the field of ADME screening and assay development.
Gastrointestinal bioavailibility is the ability of a drug or other substance to be absorbed and used by the body.
The Parties will collaborate on the development of new, miniaturized, high-throughput ADME assays for pre-clinical lead optimization. The objective of the collaboration is to develop assays that will aid in the faster and more cost efficient development of drug candidates with higher chances of success prior to clinical testing.
IPSCIO Record ID: 283198
For Discontinued Licensor Compounds
— Globally Discontinued Licensor Compounds, in the event that the Swiss Licensor determines, or is forced, to discontinue the development or the global commercialization of a Licensor Product based on a Licensor Compound or an Active Licensee Compound Derivative, such Licensor Compound or Active Licensee Compound Derivative being referred to herein as a Globally Discontinued Novartis Compound, and if Licensor, at its sole discretion, decides to license to a Third Party such Globally Discontinued Licensor Compound, then Licensor shall notify Licensee in writing of the occurrence of the above. Licensee shall then have the right of first refusal.
— Locally Discontinued Licensor Compounds, in the event that in any country, following the First Commercial Sale of a Licensor Product based on a Licensor Compound or an Active Licensee Compound Derivative, there is a continuous one (1) year period in which no such Licensor Product is sold in such country, and if Licensor, at its sole discretion, decides to license to a Third Party such Locally Discontinued Licensor Compound, Licensor shall notify Licensee in writing of the occurrence of the above. Licensee then
shall have the right of first refusal.
This agreement also includes exclusive, non-exclusive and co-exclusive grants from Licensee to Licensor.
VITA TM or Validation In Vivo of Targets for Anti-infectives shall mean Licensors proprietary technology for the validation of anti-infective targets during an established infection in a mouse model system and the development of assays.
The technology couples the validation of target proteins in a pathogen during an established infection in an animal with assay development. The assay is used in high throughput screening to discover novel drug leads that act on therapeutically relevant targets. It is broadly applicable to a number of different targets, including proteins encoded by open reading frames (ORFs), which have previously been intractable to traditional screening paradigms.
IPSCIO Record ID: 289212
Licensor is the owner of U.S. Patent 5,585,277, and U.S. Patent No. 5,679,582.
Atlas Technology shall mean the methods and processes generally disclosed in the specifications and claims of the `277 patent, the `582 patent and/or International Application No. PCT/US96/19698.
ThermoFluor Screening Technology shall mean the methods, processes and apparatus generally disclosed in the specifications and claims of U.S. Patent No. 6,020,141 and/or allowed U.S. Patent Application Serial no. 08/853,459.
Licensor was granted a limited, nonexclusive license to the method claims of ThermoFluor screening technology. As part of this settlement agreement, until March 7, 2003, Licensee is precluded from using ThermoFluor screening technology in the Hepatitis C Virus infection area as part of collaborative agreements or as part of our internal drug programs. In addition, Licensee is precluded from using ThermoFluor screening technology as part of more than one collaboration agreement in the area of infection.
During the Restriction Period, Licensor may refer to Licensee any third parties that have requested that Licensor screen multiple targets to identify leads or drugs that are effective in any field other than Infection.
Licensee shall be free to use ThermoFluor Screening Technology without restriction in any Licensee Internal Program, except in the Hepatitis C Virus Field during the Restriction Period, and to license or transfer, in any manner, any compounds discovered or optimized through such use of ThermoFluor Screening Technology. Licensee shall not use ThermoFluor Screening Technology in the Hepatitis C Virus Field during the Restriction Period.
ThermoFluor screening process and our ability to rapidly select and synthesize compounds from our libraries compress an important segment of the R&D process, from assay set-up to the generation of a series of lead compounds with potential in vivo efficacy, from fourteen to thirty months at many pharmaceutical companies to as little as seven to ten months. This is expected to reduce resources required and development costs per target, allow more targets to be discovered with a given set of resources and accelerate time to market of successful drugs
Licensee is a post-genomics drug discovery company that has developed a unique integration of proprietary technologies to provide an accelerated and improved methodology for gene-to-clinic small molecule drug discovery.
IPSCIO Record ID: 282921
Licensor grants to the Canadian Licensee, on a Screen-by-Screen basis, a world-wide, non-transferable, non-exclusive license, without the right to grant sublicenses, under Licensor Technology to make and use any Screen and use any Screening Supplies paid for by Licensee.
Agreement Compound shall mean any Hit or Derivative.
Screen shall mean an assay developed by Licensor pursuant to this Agreement to an agreed molecular target.
Licensor designs, develops, and manufactures proprietary fluorescent bioassay technologies and chemistries used therein for screening systems, useful for the acceleration of novel drug discovery and to increase the productivity of drug discovery programs.
Licensee will then proceed with a medicinal chemistry program to develop drug candidates from which pharmaceutical products may be derived.